The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
- 18 August 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 30 (12), 2413-2416
- https://doi.org/10.1038/leu.2016.233
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPNLeukemia, 2015
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patientsAmerican Journal of Hematology, 2014
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactLeukemia, 2014
- Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapyNature Reviews Cancer, 2014
- SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2New England Journal of Medicine, 2013
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cellsOncoImmunology, 2013
- HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer PatientsCancer Research, 2013
- Spontaneous Immunity against Bcl-xL in Cancer PatientsPublished by The American Association of Immunologists ,2005
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002